Department of Medical Life Sciences and Department of Medical Sciences (Graduate School), College of Medicine, The Catholic University of Korea 1 , 222 Banpo-daero, Seocho-gu, Seoul 06591
Auto-generated profile, based on publicly available information
Donghyun Lee
Department of Medical Life Sciences and Department of Medical Sciences (Graduate School), College of Medicine, The Catholic University of Korea 1 , 222 Banpo-daero, Seocho-gu, Seoul 06591
Vesicles such as liposomes, polymersomes, and exosomes have been widely used as drug delivery carriers; however, peptide vesicles (peptidesomes) despite their potential utility are far less well developed. Peptidesomes are distinctive because peptides play dual roles as a self-assembly building block and a bioactive functional unit. In order for peptidesomes to become successful nanodrugs, the issues related to differences in nanostructural properties between in vitro and in vivo conditions should be addressed. Here, we delineate a multivariate approach to feedback control the structures of peptide building blocks, nanoparticle size, drug loading process, nanoparticle aggregation, cytotoxicity, cell targeting capability, endosome disruption function, protease resistance, and in vivo performance, which eventually enabled the successful development of a highly efficacious peptidesome for in vivo cancer therapy. This study lays the groundwork for the successful in vivo translation of peptide nanodrugs.
For a long time, efficient and safe gene delivery has been a key issue in gene therapy. In particular, after the Nobel Prize in Chemistry for clustered regularly interspaced short palindromic repeat (CRISPR) technology in 2020, the focus on delivery systems for genome editing has grown. In this review, we introduce the recent trends in various CRISPR delivery systems. First, we explain the impact of CRISPR in clinical settings and its history. We then focused on the physics of gene delivery systems, particularly regarding the migration of nanoparticles (NPs) under flow, cellular uptake, and formulation using microfluidics. Subsequently, various CRISPR delivery systems, both viral and non-viral, and their applications in disease therapy were introduced. Viral carriers include lentiviruses, adeno-associated viruses, and viral capsids. Exosomes, silica NPs, polymeric NPs, and lipid NPs are representative non-viral gene delivery carriers. We mainly focused on studies demonstrating promising results in animal models, not stopped at cell test considering their future potential for human application.
23 February 2024 in Journal of Drug Delivery Science and Technology